Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXSOTCMKTS:CPMVNASDAQ:KTTAOTCMKTS:SQZB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.12$0.05$0.00▼$0.78$5.13M1.186,238 shs76 shsCPMVMosaic ImmunoEngineering$0.33$0.53$0.12▼$1.13$2.38M-0.13430 shs11 shsKTTAPasithea Therapeutics$0.75-3.4%$1.10$0.69▼$7.50$5.57M0.342.07 million shs299,809 shsSQZBSQZ Biotechnologies$0.03$0.03$0.02▼$0.10N/A1.3840,246 shsN/A10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%0.00%+244.70%+301.00%-54.17%CPMVMosaic ImmunoEngineering0.00%-38.93%-32.92%-56.97%-40.26%KTTAPasithea Therapeutics0.00%-4.83%-18.28%-40.16%-84.22%SQZBSQZ Biotechnologies0.00%0.00%0.00%0.00%-37.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACPMVMosaic ImmunoEngineeringN/AN/AN/AN/AN/AN/AN/AN/AKTTAPasithea Therapeutics0.8096 of 5 stars0.05.00.00.00.01.70.6SQZBSQZ BiotechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/ACPMVMosaic ImmunoEngineering 0.00N/AN/AN/AKTTAPasithea Therapeutics 0.00N/AN/AN/ASQZBSQZ Biotechnologies 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M1.58N/AN/A($2.06) per share-0.06CPMVMosaic ImmunoEngineeringN/AN/AN/AN/A($0.94) per shareN/AKTTAPasithea TherapeuticsN/AN/AN/AN/A$10.60 per shareN/ASQZBSQZ Biotechnologies$21.48MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/AN/AN/AN/ACPMVMosaic ImmunoEngineering-$920K-$0.12N/A∞N/AN/AN/A-1,117.89%8/12/2025 (Estimated)KTTAPasithea Therapeutics-$13.90M-$10.60N/A∞N/AN/A-88.14%-81.21%8/12/2025 (Estimated)SQZBSQZ Biotechnologies-$79.46MN/A0.00∞N/AN/AN/AN/AN/ALatest SQZB, CPMV, ADXS, and KTTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025CPMVMosaic ImmunoEngineeringN/A-$0.03N/A-$0.03N/AN/A5/20/2025Q1 2025CPMVMosaic ImmunoEngineeringN/A-$0.03N/A-$0.03N/AN/A5/15/2025Q1 2025KTTAPasithea TherapeuticsN/A-$1.61N/A-$1.61N/AN/A4/15/2025Q4 2024CPMVMosaic ImmunoEngineeringN/A-$0.02N/A-$0.02N/AN/A3/24/2025Q4 2024KTTAPasithea TherapeuticsN/A-$2.41N/A-$2.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/ACPMVMosaic ImmunoEngineeringN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/ASQZBSQZ BiotechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/ACPMVMosaic ImmunoEngineeringN/A0.020.02KTTAPasithea TherapeuticsN/A3.843.84SQZBSQZ BiotechnologiesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%CPMVMosaic ImmunoEngineeringN/AKTTAPasithea Therapeutics23.92%SQZBSQZ Biotechnologies12.41%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%CPMVMosaic ImmunoEngineering80.99%KTTAPasithea Therapeutics16.30%SQZBSQZ Biotechnologies16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2042.63 million42.36 millionNot OptionableCPMVMosaic ImmunoEngineering37.24 million1.38 millionNot OptionableKTTAPasithea Therapeutics37.44 million6.23 millionNot OptionableSQZBSQZ Biotechnologies120N/AN/AN/ASQZB, CPMV, ADXS, and KTTA HeadlinesRecent News About These CompaniesSQZ founder's new startup goes from zero to $1M in revenue in a yearDecember 19, 2024 | bizjournals.comSQZ Biotechnologies (OTC:SQZB) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comSTEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies CompanyFebruary 29, 2024 | businesswire.comAsset Sale and Plan of Liquidation and Dissolution Approved by SQZB ShareholdersFebruary 29, 2024 | businesswire.comIntroducing Portal BiotechnologiesDecember 12, 2023 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSQZB, CPMV, ADXS, and KTTA Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.12 0.00 (0.00%) As of 06/20/2025Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Mosaic ImmunoEngineering OTCMKTS:CPMV$0.33 0.00 (0.00%) As of 06/20/2025Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.Pasithea Therapeutics NASDAQ:KTTA$0.75 -0.03 (-3.43%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.72 -0.02 (-3.21%) As of 07:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.SQZ Biotechnologies OTCMKTS:SQZB$0.03 0.00 (0.00%) As of 06/20/2025SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
